After the market close, the New York City-based insurer reported adjusted earnings of $1.28 per share, beating the FactSet consensus of $1.15 per share.
Revenue declined 2% year-over-year to $17.7 billion but topped analysts' expectations of $17.2 billion.
Premiums, fees and other revenue fell 1% year-over-year to $13.1 billion for the period.
Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B.
MetLife's strengths such as its reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had somewhat weak growth in earnings per share.
You can view the full analysis from the report here: MET
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.